Designing cost-efficient randomized trials by using flexible recruitment strategies

详细信息    查看全文

• 作者：Menggang Yu (1)
  Jingwei Wu (2)
  Debra S Burns (3)
  Janet S Carpenter (4)
  
• 关键词：Interaction ; Clinical trial ; Cost saving ; Recruitment ; Power ; Sample size
• 刊名：BMC Medical Research Methodology
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：12
• 期：1
• 全文大小：310KB
• 参考文献：1. The Federation of American Societies for Experimental Biology: Funding Crisis Threatens Progress in Biomedical Research. http://www.faseb.org/Policy-and-Government-Affairs/Data-Compilations/NIH-Research-Funding-Trends.aspx
  2. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G: Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. / Health Technol Assess 2001,5(33):1鈥?6.
  3. Maxwell SE and Delaney HD: / Designing experiments and analyzing data: a model comparison perspective. Psychology Press; 2004.
  4. Follman D. Subgroups and Interactions: / Advances in Clinical Trial Biostatistics. Edited by: GELLER NL. Chapman & Hall/CRC; 2004:121鈥?40.
  5. Carpenter JS, Yu M, Wu J, Von Ah D, Milata J, Otte JL: Evaluating the Role of Serotonin in Hot Flashes after Breast Cancer Using Acute Tryptophan Depletion. / Menopause: Journal of the North American Menopause Society 2009, 16:644鈥?2. CrossRef
  6. Allison DB, Allison RL, Faith MS, Paultre F, Pi-Sunyer FX: Power and money: designing statistically powerful studies while minimizing financial costs. / Psychological Methods 1997, 2:22鈥?3. CrossRef
  7. Julious SA: Sample sizes for clinical trials with Normal data. / Statistics in Medicine 2004, 23:1921鈥?986. CrossRef
  8. Carpenter JS, Neal JG, Payne J, Kimmick G, Storniolo AM: Cognitive-behavioral intervention for hot flashes. / Oncology Nursing Forum 2007, 34:1鈥?. CrossRef
  9. Kronenberg F: Hot flashes: epidemiology and physiology. / Ann N Y Acad Sci 1990, 592:52鈥?6. discussion 123鈥?3 CrossRef
  10. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR: Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. / Journal of the National Cancer Institute 2000, 92:1054鈥?064. CrossRef
  11. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in health postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. / JAMA 2002, 288:321鈥?3. CrossRef
  12. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walker M, Humphrey L: Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. / JAMA. 2006,295(17):2057鈥?1. CrossRef
  13. Tice JA, Grady D: Alternatives to Estrogen for Treatment of Hot Flashes: Are They Effective and Safe? / JAMA 2006,295(17):2076鈥?078. CrossRef
  14. Carpenter JS, Storniolo AM, Johns S, Monahan PO, Azzouz F, Elam JL, Johnson CS, Shelton RC: Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. / Oncologist 2007, 12:124鈥?35. CrossRef
  15. Carpenter JS, Wu J, Burns DS, Yu M: Perceived control and hot flashes in treatment-seeking breast cancer survivors and menopausal women. / Cancer Nursing 2011,17(5):536鈥?38.
  16. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2288/12/106/prepub
  
• 作者单位：Menggang Yu (1)
  Jingwei Wu (2)
  Debra S Burns (3)
  Janet S Carpenter (4)
  
  1. Department of Biostatistics & Medical Informatics, School of Medicine and Public Health, University of Wisconsin, Madison, USA
  2. Department of Biostatistics, School of Medicine, Indiana University, 901 West New York Street, Indianapolis, IN, 46202, USA
  3. Department of Music and Arts Technology, School of Engineering and Technology, Purdue University, Indianapolis, USA
  4. Department of Adult Health, School of Nursing, Indiana University, 901 West New York Street, Indianapolis, IN, 46202, USA
  

文摘

Background Sample size planning for clinical trials is usually based on detecting a target effect size of an intervention or treatment. Explicit incorporation of costs into such planning is considered in this article in the situation where effects of an intervention or treatment may depend on (interact with) baseline severity of the targeted symptom or disease. Because much larger sample sizes are usually required to establish such an interaction effect, investigators frequently conduct studies to establish a marginal effect of the intervention for individuals with a certain level of baseline severity. Methods We conduct a rigorous investigation on how to determine optimum baseline symptom or disease severity inclusion criteria so that the most cost-efficient design can be used. By using a regression model with an interaction term of treatment by symptom severity, power functions were derived for various levels of baseline symptom severity. Computer algorithms and mathematical optimization were used to determine the most cost-efficient research designs assuming either single- or dual-stage screening procedures. Results In the scenarios we considered, impressive cost savings can be achieved by informed selection of baseline symptom severity via the inclusion criteria. Further cost-savings can be achieved if a two stage screening procedure is used and there are some known, relatively inexpensively collected, pre-screening information. The amount of total cost savings are shown to depend on the ratio of the screening and intervention costs. In our investigation, we assumed that: 1) the cost of approaching available subjects for screening is constant, and 2) all variables are normally distributed. There is a need to carry out further investigations with more relaxed assumptions (e.g., skewed data distribution). Conclusions As cost becomes a more and more prominent issue in modern clinical trials, cost-saving strategies will become more and more important. Strategies, such as the ones we propose here, can help to minimize costs while maximizing knowledge generation.